


## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4883760/publications.pdf Version: 2024-02-01



f1/5% @. %

#	Article	IF	CITATIONS
1	N6-methyladenosine RNA modification in cancer therapeutic resistance: Current status and perspectives. Biochemical Pharmacology, 2020, 182, 114258.	4.4	43
2	Sulforaphane: Expected to Become a Novel Antitumor Compound. Oncology Research, 2020, 28, 439-446.	1.5	27
3	CPS1 expression and its prognostic significance in lung adenocarcinoma. Annals of Translational Medicine, 2020, 8, 341-341.	1.7	27
4	Expression and molecular profiles of the AlkB family in ovarian serous carcinoma. Aging, 2021, 13, 9679-9692.	3.1	21
5	Expression and clinical significance of CPS1 in glioblastoma multiforme. Current Research in Translational Medicine, 2019, 67, 123-128.	1.8	15
6	microRNAâ€30a attenuates TGFâ€Î²1–induced activation of pulmonary fibroblast cell by targeting FAPâ€Î±. Journal of Cellular and Molecular Medicine, 2020, 24, 3745-3750.	3.6	15
7	ALKBH1-8 and FTO: Potential Therapeutic Targets and Prognostic Biomarkers in Lung Adenocarcinoma Pathogenesis. Frontiers in Cell and Developmental Biology, 2021, 9, 633927.	3.7	13
8	The novel roles of virus infection-associated gene CDKN1A in chemoresistance and immune infiltration of glioblastoma. Aging, 2021, 13, 6662-6680.	3.1	11
9	A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma. PeerJ, 2019, 7, e7125.	2.0	11
10	CFHR1 is a potentially downregulated gene in lung adenocarcinoma. Molecular Medicine Reports, 2019, 20, 3642-3648.	2.4	9